Partners
The Company has established partnerships with leading research collaborators, contract research organisations and contract manufacturing organisations in Australia and internationally, including:
University of Geneva – collaborative research agreement and contract research services for research of BARD1 biomarkers for ovarian, breast and lung cancer detection.
Griffith University Mucosal Immunology Research Group – contract research services for development and validation of BARD1 autoantibody tests.
Thermo Fisher Scientific – assay development agreement for Research Use Only (RUO) BARD1 kits for detection of BARD1 autoantibodies using the Luminex.
Griffith University Institute for Glycomics – Collaborative Research Agreement for development of SubB2M pan-cancer probe assays for detection of a range of cancers.
Minomic International –Collaborative Research Agreement for the development of an EXO-NET™ – GPC-1 based assay for the detection of Pancreatic Cancer.
University of QLD – UniQuest – Collaborative Research Agreement evaluating the effectiveness of EXO-NET™ for the purification of exosomes containing certain cancer markers.
VivaZome – Collaborative Research Agreement evaluating the effectiveness of EXO-NET™ for the purification VivaZome’s exosome-based therapies.
University of Sydney – Collaborative Research Agreement evaluating the effectiveness of EXO-NET™ for the purification of exosomes containing certain cancer markers